thalidomide has been researched along with Pulmonary Embolism in 22 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists." | 7.91 | Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. ( Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S, 2019) |
| "Multiple myeloma treatment with lenalidomide-based regimens is associated with risk of venous thromboembolism (VTE), particularly during concomitant use with erythropoiesis-stimulating agents (ESAs)." | 7.75 | Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. ( Brandenburg, NA; Bwire, R; Freeman, J; Knight, RD; Salomon, ML; Yang, X; Zeldis, JB, 2009) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 7.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen." | 7.74 | Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008) |
| "Thalidomide was thought to be the cause of hypercoagulability and coronary spasm, so it was ceased immediately." | 5.42 | Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report. ( Jin, X; Yang, J; Zhang, S, 2015) |
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 5.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| "As thalidomide has become an accepted component in therapeutic strategies for multiple myeloma, careful attention must be paid to the prevention of thrombosis." | 5.33 | [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone]. ( Handa, H; Irisawa, H; Karasawa, M; Matsushima, T; Miyazawa, Y; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Uchiumi, H, 2006) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| " We report a case of deep venous thrombosis (DVT) and pulmonary embolus (PE) following thalidomide use in a patient with leprosy (erythema nodosum leprosum, ENL) who was concurrently treated with prednisone, as well as a review of relevant literature." | 4.85 | Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. ( Boone, SL; Fabi, SG; Hill, C; West, DP; Witherspoon, JN, 2009) |
| "Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists." | 3.91 | Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. ( Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S, 2019) |
| " Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)." | 3.79 | Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013) |
| "Multiple myeloma treatment with lenalidomide-based regimens is associated with risk of venous thromboembolism (VTE), particularly during concomitant use with erythropoiesis-stimulating agents (ESAs)." | 3.75 | Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. ( Brandenburg, NA; Bwire, R; Freeman, J; Knight, RD; Salomon, ML; Yang, X; Zeldis, JB, 2009) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 3.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| " Screening for cancer revealed coexistence of two neoplasms: colon sigmoid cancer (operated on 6 weeks after pulmonary embolism onset), and multiple myeloma (treated successfully with thalidomide and dexamethasone)." | 3.75 | [Pulmonary embolism as a first manifestation of synchronous occurrence of two neoplasms]. ( Elikowski, W; Krokowicz, P; Lewandowska, M; Małek, M; Piotrowska-Stelmaszyk, G; Zawilska, K, 2009) |
| "Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen." | 3.74 | Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy. ( Chu, PH; Jeng, WJ; Kuo, MC; Shih, LY, 2008) |
| "Thalidomide was thought to be the cause of hypercoagulability and coronary spasm, so it was ceased immediately." | 1.42 | Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report. ( Jin, X; Yang, J; Zhang, S, 2015) |
| "Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE)." | 1.39 | Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. ( Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E, 2013) |
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 1.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| "As thalidomide has become an accepted component in therapeutic strategies for multiple myeloma, careful attention must be paid to the prevention of thrombosis." | 1.33 | [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone]. ( Handa, H; Irisawa, H; Karasawa, M; Matsushima, T; Miyazawa, Y; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Uchiumi, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Cornell, RF | 1 |
| Goldhaber, SZ | 1 |
| Engelhardt, BG | 1 |
| Moslehi, J | 1 |
| Jagasia, M | 1 |
| Harrell, S | 1 |
| Rubinstein, SM | 1 |
| Hall, R | 1 |
| Wyatt, H | 1 |
| Piazza, G | 1 |
| Chhabria, BA | 1 |
| Pannu, AK | 1 |
| Bhalla, A | 1 |
| Anderson, SM | 1 |
| Beck, B | 1 |
| Sterud, S | 1 |
| Lockhorst, R | 1 |
| Ngorsuraches, S | 1 |
| Zitomersky, NL | 1 |
| Levine, AE | 1 |
| Atkinson, BJ | 1 |
| Harney, KM | 1 |
| Verhave, M | 1 |
| Bousvaros, A | 1 |
| Lightdale, JR | 1 |
| Trenor, CC | 1 |
| Bagratuni, T | 1 |
| Kastritis, E | 1 |
| Politou, M | 1 |
| Roussou, M | 1 |
| Kostouros, E | 1 |
| Gavriatopoulou, M | 1 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kanelias, N | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| Shah, JJ | 1 |
| Stadtmauer, EA | 1 |
| Abonour, R | 1 |
| Cohen, AD | 1 |
| Bensinger, WI | 1 |
| Gasparetto, C | 1 |
| Kaufman, JL | 1 |
| Lentzsch, S | 1 |
| Vogl, DT | 1 |
| Gomes, CL | 1 |
| Pascucci, N | 1 |
| Smith, DD | 1 |
| Orlowski, RZ | 1 |
| Durie, BG | 1 |
| Zhang, S | 2 |
| Yang, J | 1 |
| Jin, X | 1 |
| Yang, X | 1 |
| Brandenburg, NA | 1 |
| Freeman, J | 1 |
| Salomon, ML | 1 |
| Zeldis, JB | 1 |
| Knight, RD | 1 |
| Bwire, R | 1 |
| Talamo, GP | 1 |
| Ibrahim, S | 1 |
| Claxton, D | 1 |
| Tricot, GJ | 1 |
| Fink, LM | 1 |
| Zangari, M | 1 |
| Fabi, SG | 1 |
| Hill, C | 1 |
| Witherspoon, JN | 1 |
| Boone, SL | 1 |
| West, DP | 1 |
| Elikowski, W | 1 |
| Lewandowska, M | 1 |
| Małek, M | 1 |
| Krokowicz, P | 1 |
| Piotrowska-Stelmaszyk, G | 1 |
| Zawilska, K | 1 |
| Huls, G | 1 |
| Mulder, AB | 1 |
| Rosati, S | 1 |
| van de Loosdrecht, AA | 1 |
| Vellenga, E | 1 |
| de Wolf, JT | 1 |
| Saito, M | 1 |
| Mori, A | 1 |
| Irie, T | 1 |
| Tanaka, M | 1 |
| Morioka, M | 1 |
| Larocca, A | 1 |
| Cavallo, F | 1 |
| Bringhen, S | 1 |
| Di Raimondo, F | 1 |
| Falanga, A | 1 |
| Evangelista, A | 1 |
| Cavalli, M | 1 |
| Stanevsky, A | 1 |
| Corradini, P | 1 |
| Pezzatti, S | 1 |
| Patriarca, F | 1 |
| Cavo, M | 1 |
| Peccatori, J | 1 |
| Catalano, L | 1 |
| Carella, AM | 1 |
| Cafro, AM | 1 |
| Siniscalchi, A | 1 |
| Crippa, C | 1 |
| Petrucci, MT | 1 |
| Yehuda, DB | 1 |
| Beggiato, E | 1 |
| Di Toritto, TC | 1 |
| Boccadoro, M | 1 |
| Nagler, A | 1 |
| Palumbo, A | 1 |
| Yamaguchi, S | 1 |
| Yamamoto, Y | 1 |
| Hosokawa, A | 1 |
| Hagiwara, K | 1 |
| Uezato, H | 1 |
| Takahashi, K | 1 |
| Bennett, CL | 1 |
| Schumock, GT | 1 |
| Desai, AA | 1 |
| Kwaan, HC | 1 |
| Raisch, DW | 1 |
| Newlin, R | 1 |
| Stadler, W | 1 |
| Steurer, M | 1 |
| Sudmeier, I | 1 |
| Stauder, R | 1 |
| Gastl, G | 1 |
| Miyazawa, Y | 1 |
| Irisawa, H | 1 |
| Uchiumi, H | 1 |
| Saitoh, T | 1 |
| Handa, H | 1 |
| Matsushima, T | 1 |
| Tsukamoto, N | 1 |
| Karasawa, M | 1 |
| Murakami, H | 1 |
| Nojima, Y | 1 |
| Krown, SE | 1 |
| Niedzwiecki, D | 1 |
| Hwu, WJ | 1 |
| Hodgson, L | 1 |
| Houghton, AN | 1 |
| Haluska, FG | 1 |
| Alkindi, S | 1 |
| Dennison, D | 1 |
| Pathare, A | 1 |
| Jeng, WJ | 1 |
| Kuo, MC | 1 |
| Shih, LY | 1 |
| Chu, PH | 1 |
| Esteve, E | 1 |
| Legac, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[NCT01464034] | Phase 1/Phase 2 | 136 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of enrollment) | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Pulmonary Embolism
| Article | Year |
|---|---|
Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
Topics: Adult; Drug Therapy, Combination; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous | 2009 |
Thalidomide-associated deep vein thrombosis and pulmonary embolism.
Topics: Angiogenesis Inhibitors; Humans; Pulmonary Embolism; Thalidomide; Venous Thrombosis | 2002 |
5 trials available for thalidomide and Pulmonary Embolism
| Article | Year |
|---|---|
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm | 2020 |
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Ma | 2015 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha.
Topics: Aged; Anticoagulants; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Heparin, Low-Mole | 2003 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
15 other studies available for thalidomide and Pulmonary Embolism
| Article | Year |
|---|---|
Venous thrombo-embolism: thalidomide and leprosy.
Topics: Computed Tomography Angiography; Electrocardiography; Erythema Nodosum; Humans; Leprosy, Lepromatous | 2017 |
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Mul | 2019 |
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli | 2013 |
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Diseas | 2013 |
Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report.
Topics: Anticoagulants; Atrioventricular Block; Cardiac Pacing, Artificial; Coronary Angiography; Dermatolog | 2015 |
Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Databases, Factual; Erythropoiesis; Fema | 2009 |
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Che | 2009 |
[Pulmonary embolism as a first manifestation of synchronous occurrence of two neoplasms].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Heparin, Low | 2009 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents | 2010 |
[Picture in clinical hematology no.42].
Topics: Aged; Anticoagulants; Female; Heparin; Humans; Multiple Myeloma; Pulmonary Embolism; Thalidomide; To | 2010 |
Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy.
Topics: Adrenal Cortex Hormones; Cyclosporine; Humans; Leprostatic Agents; Leprosy; Male; Middle Aged; Pulmo | 2012 |
[Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug Administration Schedul | 2006 |
Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
Topics: Administration, Oral; Aged; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple My | 2008 |
Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Multiple Myeloma; | 2008 |
[Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide].
Topics: Adult; Anticoagulants; Humans; Immunosuppressive Agents; International Normalized Ratio; Male; Pulmo | 2001 |